

VIVALDIS V
Animal Health

PetSmile

EDITION-156



FDA APPROVES FIRST EMERGENCY TREATMENT FOR NEW WORLD SCREWWORM IN CATS

- The FDA has issued an **emergency use authorization** for **Credelio CAT (lotilaner)** to treat **New World screwworm (NWS)** infestations in cats and kittens—marking the **first time any medication has been authorized for this purpose in felines**. This follows a similar authorization for dogs announced earlier in October.
- The decision is based on evidence showing strong efficacy of lotilaner against screwworm larvae. In studies, Credelio CAT demonstrated **100% larvicidal effectiveness within 24 hours** in two cats naturally infected with Old World screwworm in Malaysia. Additional studies in dogs with NWS in Brazil also showed complete elimination of larvae, supporting the drug's emergency use in cats.
- Although Credelio CAT is not officially FDA-approved for NWS treatment, the agency determined that the **potential benefits outweigh the known risks**, especially as NWS remains a declared public health threat.
- Originally approved in 2019 for **flea control and tick treatment**, Credelio CAT is available only by veterinary prescription. As an isoxazoline, it may cause neurological side effects in susceptible animals, so veterinarians should exercise caution.
- The emergency authorization will remain in place until health authorities confirm that NWS no longer poses a significant risk.



SPRAID[®]
1 x 5 ml



Vetecto Plus
Spot-on

0.9 ml



Vetecto
Spot-on

0.9/1.8/5/3.6 ml

BRISTOL VET SPECIALISTS UNVEIL NEW MINIMALLY INVASIVE HEART PROCEDURE FOR DOGS

- Bristol Vet Specialists has introduced a breakthrough surgical option for dogs suffering from mitral valve disease (MVD). The new technique, called transcatheter edge-to-edge repair (TEER), offers a minimally invasive alternative to open-heart surgery.
- TEER is performed on a beating heart using a specially engineered V-Clamp device that clips the mitral valve leaflets together, significantly reducing mitral regurgitation. The procedure is carried out through a small 6–8 cm thoracotomy and guided by real-time 3D echocardiography for precision.
- According to CVS, the group that owns Bristol Vet Specialists, dogs generally recover quickly, with most discharged within 48 hours and minimal need for intensive care. While dogs in heart failure typically survive 9–12 months, outcomes after TEER are significantly better:
 - 95% successful discharge rate
 - 85% survival at two years post-surgery
- This advancement offers new hope for dogs with MVD who are not candidates for open-heart surgery and provides a safer, faster-recovery option for affected pets.



PIMOBEN
3 x 10 tablets



PIMOBEN - Solo
3 x 10 tablets

USDA GRANTS CONDITIONAL APPROVAL TO FIRST MONOCLONAL ANTIBODY FOR CANINE PARVOVIRUS PROTECTION

Elanco Animal Health's **Canine Parvovirus Monoclonal Antibody (CPMA)** has received **conditional approval from the USDA**, becoming the **first treatment specifically targeting canine parvovirus**. The updated approval now allows CPMA to be used for **passive immunity in puppies exposed to parvo**, offering a new way to prevent this deadly disease that affects over **330,000 puppies each year**.

According to Elanco, CPMA showed **100% effectiveness** in providing passive immunity when healthy puppies (8 weeks or older) received a prophylactic dose. This expanded label is especially impactful for **shelters and high-risk environments**, where parvo outbreaks are common and resources are limited.

A shelter in Florida recently saved **27 parvo-positive puppies** using CPMA—the largest known group treated successfully with this monoclonal antibody.



**VIUSID[®]
DETOX**

30 ml



VIUSID

150 ml

VIVALDIS RECOGNIZED AS FORBES INDIA'S SELECT 200

We are honoured to announce that Kunal Khanna and Vivaldis Animal Health have been recognised in Forbes India presents DGEMS 2025 – The Select 200.

This recognition, chosen from over 5000 applications, stands as a significant milestone in our journey.

It reflects our unwavering commitment to building a scientifically driven, scalable, and globally ambitious organisation in the animal health sector. At Vivaldis, we continue to raise the benchmark for veterinary care through research-backed innovation, quality-led product development, and a deep dedication to animal well-being.

This achievement is a moment of immense pride for us and would not have been possible without the trust and support of our partners, employees, veterinarians, and everyone associated with Vivaldis. We extend our sincere gratitude to each one of you for being an integral part of our growth.

This recognition strengthens our resolve to accelerate our vision of taking Indian veterinary innovation to the global stage.

Forbes India D Globalist.

